

From: [Erin Duffy](#)
To: [Lawyer, Dennis](#)
Subject: RE: Vatera Healthcare Partners LLC ownership
Date: Thursday, March 20, 2014 9:30:13 AM

Dear Mr. Lawyer,

In answer to your question, these are the percentages (all on an as if converted basis) held by Vatera after the 1/23/2014 issuance:

Outstanding: 74.90%

Fully Diluted (includes management options): 70.13%

I hope this is helpful.

Sincerely,

Erin

Erin M Duffy, PhD

Chief Scientific Officer

Melinta Therapeutics (formerly Rib-X Pharmaceuticals)

300 George Street, Suite 301

New Haven, CT 06511

+1 203 848 6264 (office)

+1 203 624 5627 (fax)

+1 860 790 0103 (mobile)

Please note my e-mail address has changed and is now eduffy@melinta.com

From: Lawyer, Dennis [mailto:Dennis.Lawyer@nrc.gov]
Sent: Wednesday, March 12, 2014 7:44 AM
To: Erin Duffy
Subject: Vatera Healthcare Partners LLC ownership

Dr. Duffy,

I received and reviewed your letter dated February 28, 2014, describing the stock ownership and issuance changes. Since shares of stock between preferred shares class 1, 2, and 3, and common stock may be different. What is the approximate percentage of ownership of Melinta Therapeutics by Vatera Healthcare Partners, LLC after the January 23, 2014, stock issuance? You may answer by electronic mail.

Thank You,

Dennis Lawyer

Health Physicist

U.S. Nuclear Regulatory Commission

Division of Nuclear Material Safety

610-337-5366

610-337-5269 (F)

